Aventis Pharma Plans Brand Acquisitions In India Expansion Move
This article was originally published in PharmAsia News
India's Aventis Pharma plans to acquire branded drugs and expand as part of an effort to be major hub for parent Sanofi-Aventis' research and development and manufacturing. Managing Director Shallesh Ayyangar said he could not say how much the Paris-based company would invest in the India expansion. Sanofi already has two large plants in India, one for active pharmaceutical ingredients. Ayyangar said his unit plans to launch extensions or upgrades of existing drugs and drugs aimed at diabetes, oncology and the central nervous system. Sanofi also is looking at conducting more clinical trials in India. (Click here for more
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.